middle.news
How Actinogen’s Accelerated Alzheimer’s Trial Could Change the Game by 2026
9:29am on Thursday 23rd of October, 2025 AEDT
•
Healthcare
Read Story
How Actinogen’s Accelerated Alzheimer’s Trial Could Change the Game by 2026
9:29am on Thursday 23rd of October, 2025 AEDT
Key Points
XanaMIA trial enrolment accelerated, targeting ~240 participants
Interim analysis scheduled for January 2026, topline results mid Q4 2026
Successful FDA meeting clarifies streamlined approval pathway
Clinical pharmacokinetic trial confirms flexible dosing of Xanamem
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE